Cerner contract with VA could be in trouble after Shulkin’s ouster

The firing of David Shulkin, MD, as Veterans Affairs Secretary may threaten the $16 billion deal for Cerner to bring an electronic health records system to the VA, according to Nextgov.

Neither Cerner or the VA would answer questions about the deal, though the VA’s response to Nextgov declining comment on “ongoing contract negotiations” suggested no deal has been finalized. Shulkin had publicly announced and touted the deal, despite criticism about Cerner being awarded the major project without going through a competitive bidding process.

Congress had appropriated $782 million for the first fiscal year’s funding of the Cerner rollout. The entire project has been estimated to last until 2027, being implemented on a similar path as the ongoing Cerner EHR transition at the U.S. Department of Defense (DOD). Shulkin had said the contract negotiations with Cerner had been held up due to the company’s definition of interoperability—a major reason Shulkin had cited in choosing the same EHR vendor for the DOD and VA—being too limited in Shulkin’s opinion.

President Donald Trump has nominated Admiral Ronny Jackson, MD, who has served as the White House physician since 2013, to replace Shulkin.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.